Aurobindo Pharma’s net profit increased 25 per cent at Rs ₹1,032 crore in the first quarter ended June 30, 2026, compared to ₹824 crore in the corresponding quarter of the previous year.The Hyderabad-based company recorded its highest-ever quarterly revenue, up 16 per cent to ₹ 9,150 crore (₹7,868 crore). The growth was driven by strength across nearly all business segments.“We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio,’’ K. Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma, said in a release on Wednesday.“While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders,’’ he added.Published on August 5, 2026